Takeda, Affymax To Dissolve Partnership For Developing Anemia Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical plans to dissolve its partnership with Affymax and cancel joint U.S. development of their anemia drug for use with kidney dialysis after a probe failed to uncover a sometimes fatal problem.
Takeda Pharmaceutical plans to dissolve its partnership with Affymax and cancel joint U.S. development of their anemia drug for use with kidney dialysis after a probe failed to uncover a sometimes fatal problem. The two companies had applied for U.S. marketing approval, but had to recall the drug Omonty (paginesatide) after counting 98 adverse events with it, a dozen of them fatal. Takeda said an internal investigation was unable to identify the cause of the reactions, but said quality and production issues were not found to be at fault. (Click here for more
)
"Affymax, Takeda End Anemia Drug Partnership" - Dow Jones (6/13/2014)